

## Review

# Striated-for-smooth muscle replacement in the developing mouse esophagus

Mark Baguma-Nibasheka<sup>1</sup>, Anna Fracassi<sup>2</sup>, Willard J. Costain<sup>3</sup>, Sandra Moreno<sup>2</sup> and Boris Kablar<sup>1</sup>

<sup>1</sup>Department of Medical Neuroscience, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada, <sup>2</sup>Department of Science, LIME, University "Roma Tre", Rome, Italy and <sup>3</sup>Translational Bioscience, Human Health Therapeutics, National Research Council, Ottawa, ON, Canada

**Summary.** The esophagus is a muscular tube which transports swallowed content from the oral cavity and the pharynx to the stomach. Early in mouse development, an entire layer of the esophagus, the muscularis externa, consists of differentiated smooth muscle cells. Starting shortly after mid-gestation till about two weeks after birth, the muscularis externa almost entirely consists of striated muscle. This proximal-to-distal replacement of smooth muscle by the striated muscle depends on a number of factors. To identify the nature of the hypothetical "proximal" (mainly striated muscle originating) and "distal" (mainly smooth muscle originating) signals that govern the striated-for-smooth muscle replacement, we compared the esophagus of *Myf5:MyoD* null fetuses completely lacking striated muscle to the normal control using cDNA microarray analysis, followed by a comprehensive database search. Here we provide an insight into the nature of "proximal" and "distal" signals that govern the striated-for-smooth muscle replacement in the esophagus.

**Key words:** Esophagus, Myogenesis, Myogenic regulatory factors, cDNA microarrays

## Introduction

The esophagus is a segment of the alimentary (digestive) system which transports swallowed content from the oral cavity and the pharynx to the stomach. The wall of the mouse esophagus consists of mucosa, submucosa, muscularis externa (ME) and adventitia (connective tissue). The esophageal mucosa consists of nonkeratinized stratified squamous epithelium, connective tissue of the lamina propria and smooth muscle cells of the muscularis mucosae. The esophageal submucosa consists of connective tissue. The esophageal ME consists of two layers of muscle separated by connective tissue and the myenteric (Auerbach's) plexus. Early in mouse development, the entire ME consists of differentiated smooth muscle cells, but starting at embryonic day (E) 12.5 till about postnatal day (P) 14, the ME almost entirely consists of striated muscle and this proximal-to-distal replacement of smooth muscle by the striated muscle depends on a number of factors, including the myogenic regulatory factors such as *Myf5* and *MyoD* (Kablar et al., 2000; Reddy and Kablar, 2004 and the references therein).

The striated-for-smooth muscle replacement is a fascinating phenomenon whose orchestration, if disturbed, may have a number of clinically relevant implications collectively known as esophageal motility disorders. It is therefore the focus of our manuscript to contribute in revealing the molecular players that potentially have a role in: recruiting the striated muscle precursor cells, replacing differentiated smooth muscle cells by the striated muscle, and instructing other cellular and morphogenetic mechanisms underlying the striated-

for-smooth muscle replacement process.

It is a fundamental fact in histology that the body consists of only four basic tissue types: epithelium, connective tissue, muscle and nervous tissue. There is another example of tissue replacement during development, where the embryonic skeleton made of hyaline cartilage is replaced by the bone. While both the cartilage and the bone are connective tissues, skeletal-for-smooth muscle replacement is therefore the only example of a naturally occurring tissue replacement within the category of muscle basic tissue types (includes smooth and cardiac muscle).

Currently, the striated-for-smooth muscle replacement in the esophagus is described in the following manner (Krauss et al., 2016 and the references therein): *Mesp1* expressing cranial mesoderm progenitor cells, also expressing *Tbx1*, give rise to migratory *Isl1* expressing esophageal striated muscle cell progenitors. These cells arrive to the upper tip of the developing esophagus, within the developing ME, and express first *Pax7* (proliferating striated muscle-like progenitors) and then additionally *Myf5* and *MyoD* (committing to the striated muscle-like lineage muscle progenitors). This area, known as “transition zone”, also contains differentiating and differentiated myoblasts (also *myogenin* expressing). The transition zone moves in proximal-to-distal direction, while smooth muscle cells undergo fascicular reorientation and are mostly located distal to the descending transition zone. The identity of “proximal” (promote movements distally) and “distal” (promote fascicular reorientation) signals is unknown, but the striated muscle cells in the transition zone may be the source of these signals.

It is important to state that there are other views on this process. For example, the presence of numerous apoptotic smooth muscle cells, described in the literature (Wörl and Neuhuber, 2005; Wörl et al., 2009), has not been entirely accounted for by the current view on the striated-for-smooth muscle replacement in the esophagus, and therefore there is a possibility that apoptosis is the main reason for the disappearance of smooth muscle cells during esophageal development. Another example is the hypothesis of smooth-to-striated muscle transdifferentiation, connected to the lack of observable apoptotic smooth muscle cells in the developing esophagus (Patapoutian et al., 1995; Kablar et al., 2000).

In fact, approximately two decades ago, we studied striated muscle development in the esophagus of *Myf5:MyoD* null embryos and fetuses and found that striated muscle in the esophagus cannot be found in the absence of these two myogenic regulatory factors (Kablar et al., 2000). In order to identify “proximal” and “distal” signals that govern the striated-for-smooth muscle replacement in the esophagus we compared the esophagus of *Myf5:MyoD* null fetuses completely lacking striated muscle to the normal control using cDNA microarray analysis and performed a comprehensive literature and database search and

communicated with a number of scientists. Here we provide some insights into the nature of hypothetical “proximal” (striated muscle originating or “striated”) and distal (smooth muscle originating or “smooth”) signals that govern the striated-for-smooth muscle replacement in the esophagus.

## Materials and methods

### *Animal breeding and fetal collection*

Double-mutant (*Myf5*<sup>-/-</sup>:*MyoD*<sup>-/-</sup>) fetuses were obtained by the interbreeding of heterozygous (*Myf5*<sup>+/-</sup>:*MyoD*<sup>+/-</sup>) parents, as previously described (Rudnicki et al., 1993). All fetuses were collected by Cesarean section at E18.5 and genotyped by PCR using *Myf5* and *MyoD* primers (Inanlou and Kablar, 2005). In addition, the presence or absence of skeletal muscle was confirmed by myosin-fast immunostaining (data not shown). Animal use and care was in accordance with all institutional guidelines.

### *RNA isolation and analysis*

Total esophagus RNA was isolated from two wild-type and two *Myf5*<sup>-/-</sup>:*MyoD*<sup>-/-</sup> fetuses using the RNeasy™ kit from Qiagen, Mississauga, Ont., Canada, according to the manufacturer’s instructions. For each group of fetal esophagi (wild-type or mutant), RNA was pooled to minimize the effect of individual differences. Fluorescent labeling of cRNA fragments obtained from the pooled samples and their simultaneous hybridization to MOE430 2.0 GeneChip mouse genome arrays was performed at the Ottawa Genome Centre according to standard Affymetrix (Santa Clara, CA) protocols as described in Seale et al. (2004). The hybridized chips were then scanned and the results analyzed using the Affymetrix statistical expression algorithms to obtain the expression ratios and fold changes between the wild-type and double-mutant fetuses’ esophagus.

## Results

Microarray analysis identified a large number of genes that were differentially expressed between the control and the double-mutant esophagus, and an arbitrary cut-off value of 4-fold was chosen as a means of determining the up- and down-regulated probesets, respectively. A total of 133 named genes met this criterion. Thirty-five genes were up-regulated more than 4-fold (Table 1), whereas a total of 98 were down-regulated (Table 2). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE122017 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122017>).

Tables 1 and 2 also show that a great majority of the named genes are measurably expressed in the skeletal

## Esophageal striated muscle

muscle and small intestine (smooth muscle) of the normal adult mouse (Su et al., 2002).

Our next step was to identify for each of the 133 named genes a genetically engineered (mostly knockout) mouse and their phenotypes. We searched the MGI ([www.informatics.jax.org](http://www.informatics.jax.org)) and PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>) to gather this information. Seven up-regulated genes had a knockout and several were displaying the potentially relevant phenotype (Table 3), whereas 43 down-regulated genes had a knockout and several were displaying the potentially relevant phenotype (Table 4). However, no direct evidence was found regarding the “esophageal” phenotype.

Considering that, after detailed analysis and reading of the available literature, it was still not possible to detect any esophagus-specific phenotype in the knockout mice identified, we decided to contact the authors of the

relevant papers (as listed in Tables 3 and 4). It was not clear from the papers if the topic was not studied or simply not described, since in many cases describing an esophageal phenotype would not be relevant to the topic of the original publication. In other words, the papers listed in Tables 3 and 4 contained only the aspects of the knockout mouse phenotype relevant to the original scope of the paper, and that scope was not the esophagus. This is why we assumed that the esophagus-related data may be known, but have remained unreported due to the lack of their relevance to the topic of the original publication. With that in mind, we communicated with all the principal authors of the knockout mice publications from Tables 3 and 4, and asked specific, esophagus-related phenotype questions. The esophagus-related phenotype questions pertained to any morphological or/and functional alterations in the esophagus: dysphagia (difficulty swallowing), achalasia (impaired esophageal

**Table 1.** Genes up-regulated  $\geq 4$ -fold in E18.5 *Myf5*<sup>-/-</sup>;*MyoD*<sup>-/-</sup> mutant mouse esophagus, sorted by function and log<sub>2</sub> (ratio) expression value.

| Gene                 | log <sub>2</sub> (ratio) | Gene Title   | SM <sup>a</sup> | SI    | Molecular Function    |
|----------------------|--------------------------|--|-----------------|-------|-----------------------|
| <i>Mcm6</i>          | 4.15                     | minichromosome maintenance deficient 6 (MIS5 homolog, <i>S. pombe</i> ) ( <i>S. cerevisiae</i> ) | 568             | 3366  | Transcription         |
| <i>2810047C21Rik</i> | 4.02                     | RIKEN cDNA 2810047C21 gene   | 195             | 162   | Factor Activity       |
| <i>Eif2s3y</i>       | 7.38                     | eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked                  | 2523            | 1006  |                       |
| <i>Ttc41</i>         | 5.48                     | tetratricopeptide repeat domain 41   | 39              | 31    |                       |
| <i>Ddx3y</i>         | 5.26                     | DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked   | 107             | 90    | Catalytic Activity    |
| <i>Trim12a</i>       | 4.56                     | tripartite motif-containing 12A  | 96              | 88    |                       |
| <i>Arg2</i>          | 4                        | arginase type II   | 64              | 51530 |                       |
| <i>lbsp</i>          | 5.34                     | integrin binding sialoprotein  | 101             | 95    | Structural or         |
| <i>Cadm2</i>         | 5.33                     | cell adhesion molecule 2   | 243             | 219   | Cytoskeletal          |
| <i>Col4a6</i>        | 4.31                     | collagen, type IV, alpha 6   | 52              | 43    | and Cell              |
| <i>Cplane1</i>       | 4.03                     | ciliogenesis and planar polarity effector 1  | 119             | 116   | Adhesion Activity     |
| <i>LOC665506</i>     | 4.83                     | (T-cell receptor beta-2 chain C region-like)   | NA <sup>c</sup> | NA    |                       |
| <i>Wnt9b</i>         | 4                        | wingless-type MMTV integration site 9B   | 56              | 53    | Receptor and          |
| <i>Lman1</i>         | 5.18                     | lectin, mannose-binding, 1   | 1841            | 3920  | Signal Transduction   |
| <i>March4</i>        | 4.05                     | membrane-associated ring finger (C3HC4) 4  | NA              | NA    | Activity              |
| <i>Mroh7</i>         | 5.37                     | maestro heat-like repeat family member 7   | 121             | 157   |                       |
| <i>H2-T24</i>        | 4.34                     | histocompatibility 2, T region locus 24  | 142             | 128   | Immune Response       |
| <i>Spesp1</i>        | 4.8                      | sperm equatorial segment protein 1   | 115             | 99    |                       |
| <i>Glcci1</i>        | 4.67                     | glucocorticoid induced transcript 1  | 972             | 1302  | Other Processes       |
| <i>F9</i>            | 4.41                     | coagulation factor IX  | 44              | 41    | (fertilization, blood |
| <i>Slx1l</i>         | 4.22                     | Slx-like 1   | 605             | 329   | clotting, cell cycle) |
| <i>Astx</i>          | 5.39                     | amplified spermatogenic transcripts X encoded  | NA              | NA    |                       |
| <i>4921504E06Rik</i> | 5.01                     | RIKEN cDNA 4921504E06 gene   | 56              | 52    |                       |
| <i>8030497O21Rik</i> | 4.87                     | RIKEN cDNA 8030497O21 gene   | 55              | 53    |                       |
| <i>Urm1</i>          | 4.61                     | ubiquitin related modifier 1 homolog ( <i>S. cerevisiae</i> )                                    | 184             | 259   |                       |
| <i>Cnnm1</i>         | 4.36                     | cyclin M1  | 62              | 59    |                       |
| <i>9330175H22Rik</i> | 4.43                     | RIKEN cDNA 9330175H22 gene   | 138             | 368   |                       |
| <i>A730041O05Rik</i> | 4.34                     | RIKEN cDNA A730041O05 gene   | NA              | NA    |                       |
| <i>8430437N05Rik</i> | 4.29                     | RIKEN cDNA 8430437N05 gene   | 101             | 92    |                       |
| <i>5430437J10Rik</i> | 4.28                     | RIKEN cDNA 5430437J10 gene   | 85              | 82    | Not yet specified     |
| <i>D16ErtD778e</i>   | 4.19                     | DNA segment, Chr 16, ERATO Doi 778, expressed  | NA              | NA    |                       |
| <i>6330571C24Rik</i> | 4.18                     | RIKEN cDNA 6330571C24 gene   | 89              | 79    |                       |
| <i>4930563E18Rik</i> | 4.14                     | RIKEN cDNA 4930563E18 gene   | 94              | 88    |                       |
| <i>4930549O18Rik</i> | 4.03                     | RIKEN cDNA 4930549O18 gene   | 208             | 160   |                       |
| <i>4930523O13Rik</i> | 4                        | RIKEN cDNA 4930523O13 gene   | 129             | 117   |                       |

<sup>a</sup>: expression (arbitrary units) in the skeletal muscle (SM). <sup>b</sup>: small intestine (SI), of the normal adult mouse (Su et al., 2002). <sup>c</sup>: NA: data not available.

## Esophageal striated muscle

peristalsis and a lack of lower esophageal sphincter relaxation during swallowing), gastroesophageal reflux, and the presence of striated muscle, muscular

dystrophies and myopathies. Some of these symptoms could also result in failure to thrive, pneumonias and an early (e.g., neonatal) death, which were in some cases

**Table 2.** Genes down-regulated  $\geq 4$ -fold in E18.5 *Myf5*<sup>-/-</sup>:*MyoD*<sup>-/-</sup> mutant mouse esophagus, sorted by function and  $\log_2$  (ratio) expression value.

| Gene           | $\log_2$ (ratio) | Gene Title   | SM <sup>a</sup> | SI <sup>b</sup> | Molecular Function               |  |
|----------------|------------------|--|-----------------|-----------------|----------------------------------|--|
| <i>Tceal7</i>  | -8.7             | transcription elongation factor A (SII)-like 7             | NA <sup>c</sup> | NA              |                                  |  |
| <i>Lmcd1</i>   | -6.26            | LIM and cysteine-rich domains 1                            | 6433            | 54              |                                  |  |
| <i>Pax7</i>    | -5.69            | paired box gene 7  | 56              | 53              |                                  |  |
| <i>Smyd1</i>   | -5.13            | SET and MYND domain containing 1                           | 1312            | 117             |                                  |  |
| <i>Vgll2</i>   | -4.78            | vestigial like 2 homolog (Drosophila)                      | 541             | 102             |                                  |  |
| <i>Nolc1</i>   | -4.71            | nucleolar and coiled-body phosphoprotein 1                 | 1011            | 1135            |                                  |  |
| <i>Egr2</i>    | -4.44            | early growth response 2                                    | 129             | 107             | Transcription<br>Factor Activity |  |
| <i>Prox1</i>   | -4.42            | prospero-related homeobox 1                                | 148             | 137             |                                  |  |
| <i>Jrk</i>     | -4.4             | jerky  | 59              | 55              |                                  |  |
| <i>Shox2</i>   | -4.21            | short stature homeobox 2                                   | 83              | 75              |                                  |  |
| <i>Myog</i>    | -4.12            | myogenin   | 233             | 391             |                                  |  |
| <i>Hbp1</i>    | -4.11            | high mobility group box transcription factor 1             | 6079            | 1771            |                                  |  |
| <i>Isl1</i>    | -4.03            | ISL1 transcription factor, LIM/homeodomain                 | 50              | 48              |                                  |  |
| <i>Onecut2</i> | -4.01            | one cut domain, family member 2                            | 49              | 47              |                                  |  |
| <i>Myh1</i>    | -10.1            | myosin, heavy polypeptide 1, skeletal muscle, adult        | 26932           | 78              |                                  | Structural,<br>Cytoskeletal,<br>and Motor Activity |
| <i>Tnnc2</i>   | -9.83            | troponin C2, fast  | 472085          | 59              |                                  |  |
| <i>Ttn</i>     | -8.3             | titin  | 15190           | 1446            |                                  |  |
| <i>Neb</i>     | -7.92            | nebulin  | NA              | NA              |                                  |  |
| <i>Myh3</i>    | -7.71            | myosin, heavy polypeptide 3, skeletal muscle, embryonic    | NA              | NA              |                                  |  |
| <i>Mybph</i>   | -7.57            | myosin binding protein H                                   | 24299           | 65              |                                  |  |
| <i>Myl3</i>    | -7.24            | myosin, light polypeptide 3                                | 34937           | 120             |                                  |  |
| <i>Tnni1</i>   | -7.21            | troponin I, skeletal, slow 1                               | 1125            | 42              |                                  |  |
| <i>Tpm3</i>    | -7.2             | tropomyosin 3, gamma                                       | 7002            | 41892           |                                  |  |
| <i>Myom2</i>   | -7.12            | myomesin 2   | 25233           | 47              |                                  |  |
| <i>Myh8</i>    | -7               | myosin, heavy polypeptide 8, skeletal muscle, perinatal    | 389             | 145             |                                  |  |
| <i>Acta1</i>   | -6.51            | actin, alpha 1, skeletal muscle                            | 418196          | 460             |                                  |  |
| <i>Myl1</i>    | -6.22            | myosin, light polypeptide 1                                | 473430          | 397             |                                  |  |
| <i>Mylpf</i>   | -6.19            | myosin light chain, phosphorylatable, fast skeletal muscle | 315081          | 35              |                                  |  |
| <i>Myoz2</i>   | -6.13            | myozenin 2   | 8363            | 43              |                                  |  |
| <i>Myh6</i>    | -5.79            | myosin, heavy polypeptide 6, cardiac muscle, alpha         | 109             | 103             |                                  |  |
| <i>Tnnc1</i>   | -5.25            | troponin C, cardiac/slow skeletal                          | 21025           | 62              |                                  |  |
| <i>Lmod2</i>   | -5.19            | leiomodoin 2 (cardiac)                                     | 1280            | 135             |                                  |  |
| <i>Myot</i>    | -4.92            | myotilin   | 132172          | 57              |                                  |  |
| <i>Myom3</i>   | -4.81            | myomesin family, member 3                                  | 87              | 86              |                                  |  |
| <i>Cobl</i>    | -4.78            | cordon-bleu  | 212             | 15803           |                                  |  |
| <i>Synpo2l</i> | -4.69            | synaptopodin 2-like  | 4140            | 222             |                                  |  |
| <i>Ldb3</i>    | -4.66            | LIM domain binding 3                                       | 1435            | 67              |                                  |  |
| <i>Nefl</i>    | -4.46            | neurofilament, light polypeptide                           | NA              | NA              |                                  |  |
| <i>Smpx</i>    | -4.4             | small muscle protein, X-linked                             | 86156           | 199             |                                  |  |
| <i>Sgcg</i>    | -4.03            | sarcoglycan, gamma (dystrophin-associated glycoprotein)    | 1021            | 112             |                                  |  |
| <i>Wif1</i>    | -7.16            | Wnt inhibitory factor 1                                    | 141             | 119             | Catalytic Activity               |  |
| <i>Cox6a2</i>  | -7.15            | cytochrome c oxidase, subunit VI a, polypeptide 2          | 108673          | 70              |                                  |  |
| <i>Art1</i>    | -6.44            | ADP-ribosyltransferase 1                                   | 75              | 71              |                                  |  |
| <i>Akr1c14</i> | -6.25            | aldo-keto reductase family 1, member C14                   | 310             | 352             |                                  |  |
| <i>Dhrs7c</i>  | -6.05            | dehydrogenase/reductase (SDR family) member 7C             | 6131            | 44              |                                  |  |
| <i>Pgam2</i>   | -5.08            | phosphoglycerate mutase 2                                  | 133394          | 45              |                                  |  |
| <i>Capn1</i>   | -4.97            | calpain 1  | 50              | 142             |                                  |  |
| <i>Trim63</i>  | -4.68            | tripartite motif-containing 63                             | 185             | 127             |                                  |  |
| <i>Mark1</i>   | -4.43            | MAP/microtubule affinity-regulating kinase 1               | 38              | 36              |                                  |  |
| <i>Srl</i>     | -4.39            | sarcalumenin   | 133087          | 147             |                                  |  |
| <i>Acsl4</i>   | -4.37            | acyl-CoA synthetase long-chain family member 4             | 184             | 158             |                                  |  |
| <i>Padi3</i>   | -4.33            | peptidyl arginine deiminase, type III                      | 44              | 44              |                                  |  |
| <i>Mettl22</i> | -4.17            | methyltransferase like 22                                  | NA              | NA              |                                  |  |
| <i>Psm6</i>    | -4.15            | proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 | 18861           | 4256            |                                  |  |
| <i>Tecrl</i>   | -4.11            | trans-2,3-enoyl-CoA reductase-like                         | 242             | 182             |                                  |  |

## Esophageal striated muscle

indicated by the authors in Tables 3 and 4.

Here are the data obtained via “personal communications.” The most striking esophageal phenotypes were considered those with the “complete lack of striated muscle” as observed in *Mylpf* nulls (communicated by Yingcai Wang, ywang@med.miami.edu), or with “almost complete lack of striated muscle” in *Acta1* nulls (James L. Lessard, james.lessard@cchmc.org; Kristin Nowak, kristen.nowak@perkins.uwa.edu.au) and in *Myog* nulls (Frank W. Booth,

boothf@missouri.edu) and, finally, with “significantly reduced striated muscle” in *Pax7* nulls (Peter Gruss, peter.gruss@gv.mpg.de). In fact, it has been recently shown that PAX7 is required for patterning of the esophageal musculature (Chihara et al., 2015). Several years earlier, it was shown that the deletion of *Pax7* changes the mouse esophageal ME from a striated to a mixed smooth and striated muscle phenotype (Wörl et al., 2009). Finally, the “striated muscle damage” was communicated for *Ryr1* nulls (Hiroshi Takeshima,

**Table 2.** (Continued).

| Gene                 | log <sub>2</sub> (ratio) | Gene Title   | SM <sup>a</sup> | SI <sup>b</sup> | Molecular Function                                    |
|----------------------|--------------------------|--|-----------------|-----------------|---|
| <i>Actn2</i>         | -7.74                    | actinin alpha 2  | 44643           | 62              | Signal Transduction Activity                          |
| <i>Trdn</i>          | -7.64                    | triadin  | 75964           | 232             |   |
| <i>Cavin4</i>        | -6.68                    | caveolae associated 4  | 6475            | 72              |   |
| <i>Sln</i>           | -6.4                     | sarcolipin   | NA              | 106             |   |
| <i>Arhgap36</i>      | -5.26                    | Rho GTPase activating protein 36   | 198             | 155             |   |
| <i>Prex2</i>         | -5.1                     | phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 | NA              | NA              |   |
| <i>Hbs1l</i>         | -4.76                    | Hbs1-like ( <i>S. cerevisiae</i> )                                       | 6494            | 3783            |   |
| <i>Csrp3</i>         | -4.48                    | cysteine and glycine-rich protein 3                                      | 4106            | 152             |   |
| <i>LOC100047138</i>  | -4.24                    | (similar to tescalcin)   | NA              | NA              |   |
| <i>Khdrbs3</i>       | -4.15                    | KH domain containing, RNA binding, signal transduction associated 3      | 2024            | 542             |   |
| <i>Ryr1</i>          | -7.12                    | ryanodine receptor 1, skeletal muscle                                    | 98446           | 62              | Receptor or Channel and Transport or Carrier Activity |
| <i>Atp1b4</i>        | -6.9                     | ATPase, (Na+)/K+ transporting, beta 4 polypeptide                        | 69              | 65              |   |
| <i>Hfe2</i>          | -6.52                    | hemochromatosis type 2 (juvenile) (human homolog)                        | 74564           | 141             |   |
| <i>Hbb-y</i>         | -5.67                    | hemoglobin Y, beta-like embryonic chain                                  | NA              | NA              |   |
| <i>Mmgt1</i>         | -5.32                    | membrane magnesium transporter 1   | 4883            | 1438            |   |
| <i>Chrna1</i>        | -5.31                    | cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)            | 51              | 49              |   |
| <i>Abcb7</i>         | -4.53                    | ATP-binding cassette, sub-family B (MDR/TAP), member 7                   | 1293            | 448             |   |
| <i>Atp2a1</i>        | -4.34                    | ATPase, Ca++ transporting, cardiac muscle, fast twitch 1                 | 694632          | 170             |   |
| <i>Ehd1</i>          | -4.29                    | EH-domain containing 1   | 105             | 108             |   |
| <i>Nkap</i>          | -4.95                    | NFKB activating protein  | 112             | 114             |   |
| <i>Adig</i>          | -4.77                    | adipogenin   | 55              | 74              | Regulation of Cell Differentiation                    |
| <i>Unc45b</i>        | -4.7                     | unc-45 homolog B ( <i>C. elegans</i> )                                   | 7698            | 92              |   |
| <i>Klhl41</i>        | -9.47                    | kelch-like 41  | NA              | NA              | Not yet specified                                     |
| <i>Mymx</i>          | -6.69                    | myomixer, myoblast fusion factor   | NA              | NA              |   |
| <i>Txlnb</i>         | -6.65                    | taxilin beta   | 36743           | 87              |   |
| <i>Iffo1</i>         | -6.43                    | intermediate filament family orphan 1                                    | 84              | 57              |   |
| <i>Fndc5</i>         | -5.25                    | fibronectin type III domain containing 5                                 | 60              | 37              |   |
| <i>5730526G10Rik</i> | -5.04                    | RIKEN cDNA 5730526G10 gene   | NA              | NA              |   |
| <i>AA672641</i>      | -5.04                    | expressed sequence AA672641  | NA              | NA              |   |
| <i>Lmod3</i>         | -5                       | leiomodoin 3 (fetal)   | 11763           | 107             |   |
| <i>Fndc3c1</i>       | -5                       | fibronectin type III domain containing protein 3C1                       | 77              | 71              |   |
| <i>Lrrn1</i>         | -4.96                    | leucine rich repeat protein 1, neuronal                                  | 206             | 191             |   |
| <i>LOC100044533</i>  | -4.94                    | (similar to Zic protein zinc finger protein of the cerebellum 1)         | NA              | NA              |   |
| <i>Ccdc186</i>       | -4.8                     | coiled-coil domain containing 186  | 678             | 2965            |   |
| <i>Lrrc41</i>        | -4.6                     | leucine rich repeat containing 41  | 103             | 196             |   |
| <i>Thsd7b</i>        | -4.53                    | thrombospondin, type I, domain containing 7B                             | 258             | 167             |   |
| <i>Mon1b</i>         | -4.4                     | MON1 homolog b (yeast)   | 147             | 143             |   |
| <i>Cenpl</i>         | -4.4                     | centromere protein L   | NA              | NA              |   |
| <i>A1131651</i>      | -4.37                    | expressed sequence A1131651  | NA              | NA              |   |
| <i>Fam25c</i>        | -4.29                    | family with sequence similarity 25, member c                             | 268             | 226             |   |
| <i>Map3k7cl</i>      | -4.16                    | Map3k7 C-terminal like   | 69              | 65              |   |
| <i>1110002E22Rik</i> | -4.14                    | RIKEN cDNA 1110002E22 gene   | NA              | NA              |   |
| <i>4930522H14Rik</i> | -4                       | RIKEN cDNA 4930522H14 gene   | 49              | 45              |   |

<sup>a</sup>: expression (arbitrary units) in the skeletal muscle (SM). <sup>b</sup>: small intestine (SI), of the normal adult mouse (Su et al., 2002). <sup>c</sup>: NA: data not available.

takeshim@m.u.tokyo.ac.jp) and an “aberrant diaphragm” was communicated for *Atp2a1* nulls (David H. MacLennan, david.maclennan@utoronto.ca).

The next group of communicated data relate to the disturbances in muscle function. For example, “progressive muscle weakness” was observed in *Neb* nulls (communicated by Siegfried Labeit, Labeit@embl.de), whereas “impaired muscle function” was communicated for *Trdn* nulls (Isabelle Marty, isabelle.marty@ujf-grenoble.fr) and for *Srl* nulls (Hiroshi Takeshima, takeshim@mail.tains.tohoku.ac.jp).

“Myopathy” and “dystrophy” were communicated for *Ehd1* nulls (Hamid Band, hband@unmc.edu) and *Sgcg* nulls (Elizabeth M. McNally, elizabeth.mcnally@northwestern.edu), respectively. “Myopathy with dysphagia” was communicated for *Ldb3* nulls (Ju Chen, juchen@ucsd.edu). Potentially dystrophy-related “motor coordination” problems were observed in *Prex2* nulls (Heidi C.E. Welch, heidi.welch@babraham.ac.uk). In fact, we performed routine, hematoxylin and eosin stained, histological analysis of P0 and P7 *Prex2*-/- esophagi, including wildtype and heterozygote controls (kindly provided by Dr. Heidi C.E. Welch), and did not find any obvious esophageal phenotype. (N.B., we observed some signs of muscular dystrophy in several muscles of the *Prex2* nulls head, but these findings are outside of the scope of this manuscript.)

Furthermore, several phenotypes were related to problems with innervation. For example, a “neuromuscular” phenotype was communicated for *Chrn1* nulls (Kuo-Fen Lee, klee@salk.edu), while “motor innervation” problems were communicated for *Nefl* nulls (Jean-Pierre Julien, jean-pierre.julien@fmed.ulaval.ca).

Surprisingly, “excess of striated muscle fibers” was communicated for *Myoz2* nulls (Frank W. Booth, boothf@missouri.edu), whereas “disturbed smooth muscle function” was communicated for *Myh1* nulls (Leslie A Leinwand, Leslie.Leinwand@colorado.edu).

Several mutant mice were “neonatal lethal” or had “impaired growth” or/and a “failure to thrive,” with consequent early lethality. These are: *Lman1* nulls (Bin

Zhang, zhangb@ccf.org), *Wnt9b* nulls (Andrew P. McMahon, mcmahona@usc.edu), *Klhl41* (Ramirez-Martinez et al., 2017), *Mymx* (Quinn et al., 2017), *Erg2* nulls (Thomas Gridley, gridlt@mmc.org; Patrick Charnay, patrick.charnay@ens.fr), *Jrk* nulls (Miklos Toth, mtoth@med.cornell.edu), and *Onecut2* nulls (Frederic Clotman, frederic.clotman@uclouvain.be; Frederic P. Lemaigre, lemaigre@horm.ucl.ac.be). However, we performed routine histological analyses (hematoxylin and eosin staining) of E16.5, E17.5 and P0 *Lman1*-/- esophagi, including wildtype and heterozygote controls (kindly provided by Dr. Bin Zhang), and did not identify any obvious esophageal phenotype.

There were a number of mutant mice that were “embryonic lethal” at various stages: E8.5 (*Mcm6* nulls: John C. Schimenti, jcs92@cornell.edu; *Myl1* nulls: Nadia Rosenthal, nadia.rosenthal@jax.org; *Nkap* nulls: Virginia Smith-Shapiro, shapiro.virginial@mayo.edu; *Abcb7* nulls: Mark D Fleming, mark.fleming@childrens.harvard.edu), E8.5-12.5 (*Tpm3* nulls: Peter Gunning, p.gunning@unsw.edu.au; David Wieczorek, david.wieczorek@uc.edu), E9.5 (*Unc45b* nulls: www.informatics.jax.org(a)ref), E10.5 (*Smyd1* nulls: Paul D. Gottlieb, gottlieb@uts.cc.utexas.edu), E11.5 (*Isl1* nulls: Thomas M Jessell, tmj1@columbia.edu), E13.5 (*Myh6* nulls: Jeffrey Robbins, Jeff.Robbins@chmcc.org), E14.5 (*Shox2* nulls: Adriana C. Gittenberger-de Groot, acgitten@lumc.nl), and E15.5 (*Prox1* nulls: Guillermo Oliver, guillermo.oliver@stjude.org).

Lastly, there were a number of mutants whose authors communicated that an esophageal phenotype would be “unlikely” (based on other features of the phenotype, such as growth, feeding behavior, etc.) in their mice even if examined: *Ibsp* (Malaval et al., 2008), *Spesp1* nulls (Masaru Okabe, okabe@gen-info.osaka-u.ac.jp), *F9* nulls (Darrel W. Stafford, dws@email.unc.edu), *Col4a6* nulls (Yoshi Ninomaya, yoshinin@cc.okayama-u.ac.jp), *Arg2* nulls (Jaye P.F. Chin-Dusting, jaye.chin-dusting@bakeridi.edu.au), *Ttn* nulls (Michael Gotthardt, gotthardt@mdc-berlin.de), *Wif1* nulls (David M. Thomas, david.thomas@pertermac.org), *Cox6a2* nulls

**Table 3.** Genes up-regulated  $\geq 4$ -fold in E18.5 *Myf5*<sup>-/-</sup>:*MyoD*<sup>-/-</sup> mutant mouse esophagus with knockout (null mutant) mouse models (in order of log<sub>2</sub> ratio).

| Gene          | Comments on Deletion Mutants   | Reference                                |
|---------------|--|--|
| <i>Ibsp</i>   | Bone is undermineralized in fetuses and young adults   | Malaval et al., 2008                     |
| <i>Lman1</i>  | Prewaning lethality, with dilated endoplasmic reticulum in hepatocytes   | Zhang et al., 2011                       |
| <i>Spesp1</i> | Males show decreased fertilization frequency and delayed fertilization   | Fujihara et al., 2010                    |
| <i>F9</i>     | Premature death due to abnormal blood coagulation; reduced levels of factor IX   | Lin et al., 1997                         |
| <i>Col4a6</i> | Viable, fertile and healthy with no apparent phenotypic defects  | Fox et al., 2007                         |
| <i>Mcm6</i>   | Prenatal or premature lethality, chromosomal instability, abnormal erythrocyte morphology, increased tumor incidence                     | Chuang et al., 2010; Pruitt et al., 2007 |
| <i>Wnt9b</i>  | Neonatal lethality, disrupted ureteric bud branching, impaired Mullerian duct formation, and incompletely penetrant cleft lip and palate | Carroll et al., 2005                     |
| <i>Arg2</i>   | Viable, but with hypertension and elevated plasma arginine levels  | Shi et al., 2001; Huynh et al., 2009     |

## Esophageal striated muscle

**Table 4.** Genes down-regulated  $\geq 4$ -fold in E18.5 *Myf5*<sup>-/-</sup>:*MyoD*<sup>-/-</sup> mutant mouse esophagus with knockout (null mutant) mouse models (in order of log2 ratio).

| Gene           | Comments on Deletion Mutants  | Reference                                    |
|----------------|---|--|
| <i>Myh1</i>    | Kyphosis, reduced growth, muscular weakness, and abnormal kinetics of muscle contraction and relaxation   | Acakpo-Satchivi et al., 1997                 |
| <i>Klhl41</i>  | Defective sarcomeric formation; neonatal death  | Ramirez-Martinez et al., 2017                |
| <i>Ttn</i>     | Embryogenesis defects; vascular, cardiac and skeletal muscle defects causing growth retardation, muscle weakness, abnormal posture, and death between embryonic day 11.5 and 8 weeks of age | Lane, 1985;<br>Weinert et al., 2006          |
| <i>Neb</i>     | Growth retardation, kyphosis, abnormal gait, progressive muscle weakness, and death within 3 weeks  | Witt et al., 2006                            |
| <i>Trdn</i>    | Viable and fertile but with impaired skeletal muscle function   | Oddoux et al., 2009                          |
| <i>Tpm3</i>    | Early embryonic death, prior to blastocyst formation  | Hook et al., 2004                            |
| <i>Wif1</i>    | Viable and fertile but highly susceptible to osteosarcomas  | Kansara et al., 2009                         |
| <i>Cox6a2</i>  | Cardiac dysfunction due to abnormal ventricular filling or diastolic dysfunction under maximal cardiac load   | Radford et al., 2002                         |
| <i>Ryr1</i>    | Skeletal abnormalities, fragmented muscle fibers, and perinatal death from respiratory failure  | Takehima et al., 1994                        |
| <i>Mymx</i>    | Abnormal skeletal muscle morphology; neonatal death   | Quinn et al., 2017                           |
| <i>Hfe2</i>    | Decreased hepcidin expression, severe iron overload, and male sterility   | Niederkofler et al., 2005                    |
| <i>Acta1</i>   | Scoliosis, reduced body weight/size, atrophy of brown adipose tissue, depleted glycogen stores, muscle weakness, and death by postnatal day 10  | Crawford et al., 2002                        |
| <i>Sln</i>     | Increased cardiac contractility, with no apparent change in cardiac muscle morphology   | Babu et al., 2007                            |
| <i>Myl1</i>    | Developmental delay, failure to form mesoderm, and death by embryonic day 8.5   | Jiang et al., 2002                           |
| <i>Mylpf</i>   | Completely lacking skeletal muscle, all die immediately after birth, presumably due to respiratory failure  | Wang et al., 2007                            |
| <i>Myoz2</i>   | Excess of skeletal muscle fibers; cardiac hypertrophy when chronically stressed   | Frey et al., 2004                            |
| <i>Myh6</i>    | Embryonic death by day 13, associated with gross heart defects  | Jones et al., 1996                           |
| <i>Pax7</i>    | Retarded growth, muscle weakness, craniofacial malformations, abnormal gland morphology, and death within three weeks   | Mansouri et al., 1996                        |
| <i>Hbb-y</i>   | Viable, with a normal phenotype through adulthood   | Hu et al., 2007                              |
| <i>Chrna1</i>  | Neonatal lethality, kyphosis, carpoposis, abnormal endplate potential, increased motor neuron number, and abnormal neuromuscular synapse morphology   | An et al., 2010                              |
| <i>Lmod2</i>   | Contractile dysfunction and dilated cardiomyopathy; death within a month  | Pappas et al., 2015                          |
| <i>Smyd1</i>   | Enlarged heart, and developmental abnormalities of the right ventricle; embryonic death at day 10.5   | Gottlieb et al., 2002                        |
| <i>Prex2</i>   | Motor coordination defects, more pronounced in females, progressively worsening with age  | Donald et al., 2008                          |
| <i>Capn1</i>   | Decreased platelet aggregation and defective clot retraction  | Azam et al., 2001                            |
| <i>Nkap</i>    | Thymus hypoplasia and impaired T cell differentiation with decreased total thymocytes   | Pajerowski et al., 2009                      |
| <i>Myot</i>    | Normal lifespan and fertility, and no abnormal phenotype detected   | Moza et al., 2007                            |
| <i>Cobl</i>    | Exencephaly due to defects in neural tube closure   | Carroll et al., 2003                         |
| <i>Unc45b</i>  | Embryonic lethality at day 9 without placental abnormalities  | www.informatics.jax.org(a)                   |
| <i>Trim63</i>  | Cardiac hypertrophy, and most die in two weeks with heart failure   | Witt et al., 2008                            |
| <i>Ldb3</i>    | Myopathy, dysphagia, heart vascular congestion, dilated heart ventricles, cyanosis, respiratory distress, and death within a few days after birth   | Zhou et al., 2001                            |
| <i>Abcb7</i>   | Hemizygous male and heterozygous female mice carrying a maternally inherited null allele display prenatal lethality   | Pondarre et al., 2006                        |
| <i>Csrp3</i>   | Heart ventricle dilation, hypertrophy and fibrosis, decreased contractility, and premature death  | Arber et al., 1997                           |
| <i>Nefl</i>    | Lack of neurofilaments in the axons, and motor axons are reduced in both size and number  | Zhu et al., 1997                             |
| <i>Egr2</i>    | Defective axonal migration, disrupted myelination of Schwann cells, slow respiratory and jaw opening rhythms, skeletal abnormalities, and perinatal lethality                               | Swiatek and Gridley, 1993                    |
| <i>Padi3</i>   | Morphological alterations in the hair coat  | Basmanav et al., 2016                        |
| <i>Prox1</i>   | Death by embryonic day 15 with impaired development of the lens, lymphatic system, liver and pancreas   | Wigle and Oliver, 1999                       |
| <i>Smpx</i>    | No apparent defects in heart or skeletal muscle morphology or development   | Palmer et al., 2001                          |
| <i>Jrk</i>     | Elevated seizure susceptibility, impaired postnatal growth, reduced life span, male sterility and impaired female fertility   | Toth et al., 1995                            |
| <i>Srl</i>     | Impaired calcium store functions in skeletal and cardiac muscle cells, resulting in slow contraction and relaxation phases  | Yoshida et al., 2005                         |
| <i>Acsl4</i>   | Female heterozygotes exhibit accumulation of prostaglandins in the uterus, reduced fertility with few and small litters, and very low transmission of the mutant allele                     | Cho et al., 2001                             |
| <i>Atp2a1</i>  | Respiratory distress, progressive cyanosis, and death within 2 hours after birth, the lung tissues and diaphragm muscle showing aberrant morphology   | Pan et al., 2003                             |
| <i>Ehd1</i>    | Perinatal and postnatal lethality, decreased body weight, and male infertility due to defective spermatogenesis   | Rainey et al., 2010                          |
| <i>Shox2</i>   | Abnormal heart development and pericardial edema, death by embryonic day 14   | Blaschke et al., 2007                        |
| <i>Myog</i>    | Kyphosis, muscle hypoplasia, no spontaneous movement, and death within minutes due to respiratory failure   | Hasty et al., 1993;<br>Tseng et al., 2000    |
| <i>Sgcg</i>    | Abnormalities in muscles and heart similar to muscular dystrophy  | Hack et al., 1998                            |
| <i>Isl1</i>    | Abnormal heart and pancreas development, failure to develop motor neurons, and death by embryonic day 11.5  | Pfaff et al., 1996                           |
| <i>Onecut2</i> | Abnormal liver and pancreas development, failure to thrive  | Clotman et al., 2005;<br>Dusing et al., 2010 |

(Daniel J. Garry, garry@umn.edu), *Hfe2* nulls (Silvia Arber, silvia.arber@unibas.ch), *Sln* nulls (Muthu Periasamy, periasamy.1@osu.edu), *Hbb-y* nulls (Steven Fiering, fiering@dartmouth.edu), *Lmod2* (Pappas et al., 2015), *Capn1* nulls (Athar H. Chishti, Athar\_Chishti@cchcs.org), *Myot* nulls (Monia Moza, monica.moza@helsinki.fi), *Cobl* nulls (John Klingensmith, kling@cellbio.duke.edu), *Trim63* nulls (Siegfried Labeit, Labeit@embl.de), *Csrp3* nulls (Silvia Arber, silvia.arber@unibas.ch), *Padi3* (U Basmanav et al., 2016), *Smpx* nulls (Richard P. Harvey, r.harvey@victorchang.unsw.edu.au), and *Acs14* nulls (Tokuo T. Yamamoto, tomoko-y@faculty.chiba-u.jp).

## Discussion

In order to reveal molecular players with a potential role in esophageal muscle development, we performed cDNA microarray analysis comparing *Myf5:MyoD* null esophagi with no striated muscle (Kablar et al., 2000) to the wild-type control esophagi at E18.5. We obtained a profile of genes potentially relevant to the developing esophageal striated muscle (Tables 1, 2). The differential expression patterns obtained by the microarray analysis resulted in a large number of genes, so we added another criterion, the transcriptome expression pattern (Su et al., 2002), as shown in Tables 1, 2. Lastly, we added the third criterion, the esophageal (and esophagus-related) phenotype, as published on PubMed (Tables 3, 4) or personally communicated, to gain insight into the knockout mouse phenotypes relevant to the esophageal development for each of the differentially expressed genes, when available. It is important to realize that some histopathologic and other phenotypic changes reported here as “personal communication” are not necessarily specific to the esophagus alone. For example, the dystrophy-related “motor coordination” change in the *Prex2* nulls does not relate to any esophageal phenotype.

Considering that the gene up- or down-regulation and the transcriptome expression level are criteria that are not as reliable as the knockout mouse phenotype, we decided to form conclusions primarily based on the phenotype and only secondarily (as additional, supporting information) on the level of up- or down-regulation and transcriptome expression.

Using these criteria, we propose that the potential candidates for the “proximal” or striated muscle originating signals (“striated”) are: *Mylpf* (complete lack of striated muscle in the esophagus, down-regulated 6.19 times, and more than 300,000 transcriptome expression level in the striated muscle and almost none in smooth muscle), *Acta1* (almost complete absence of striated muscle in the esophagus, down-regulated 6.51 times, and more than 400,000 transcriptome expression level in striated muscle and very low in smooth muscle), *Myog* (almost complete lack of striated muscle in the esophagus, down-regulated 4.12 times), *Pax7* (significantly reduced striated muscle in the esophagus,

down-regulated 5.69 times) and *Ryr1* (striated muscle damage in the esophagus, down-regulated 7.12 times, and almost 100,000 transcriptome expression level in striated muscle and very low in smooth muscle). *Myf5*, *MyoD* and *Mrf4* should be included in this group, considering the amount of strong evidence previously reported that supports their involvement in skeletal and esophageal striated muscle development (Rudnicki et al., 1993; Kablar et al., 2000; Reddy and Kablar, 2004; Kassar-Duchossoy et al., 2004).

Several other candidates for the “proximal” or “striated” signals could be included, based on striated muscle function, disease (e.g., myopathy and/or dystrophy) or innervation pathologies (phenotypes): *Neb* (progressive muscle weakness, down-regulated 7.92 times), *Trdn* (impaired muscle function, down-regulated 7.64 times, and almost 100,000 transcriptome expression level in the striated muscle and very low in smooth muscle), *Srl* (impaired muscle function, down-regulated 4.39 times, and more than 100,000 transcriptome expression level in striated muscle and very low in smooth muscle), *Ehd1* (myopathy and dystrophy, down-regulated 4.29 times), *Sgcg* (myopathy and dystrophy, down-regulated 4.03 times, and more than 1,000 transcriptome expression level in striated muscle and very low in smooth muscle), *Ldb3* (myopathy with dysphagia, down-regulated 4.66 times, and more than 1,000 transcriptome expression level in striated muscle and very low in smooth muscle), *Chrna1* (neuromuscular pathology, down-regulated 5.31 times), and *Nefl* (motor innervation pathology, down-regulated 4.46 times). The last two genes were included in this list because motor innervation (e.g., the neuromuscular junction development) and striated-for-smooth muscle replacement are interconnected developmental events in the esophagus (Reddy and Kablar, 2004).

The potential candidates for the “distal” or smooth muscle originating signals (“smooth”) are: *Myoz2* (excess of striated muscle, down-regulated 6.13 times) and *Myh1* (smooth muscle pathology, down-regulated 10.1 times). However, contrary to our logic behind the criteria employed here, *Myh1* has almost 30,000 transcriptome expression level in striated muscle and very low (and should have been very high) in smooth muscle (Table 2), however it was included here based on phenotype, the strongest of the three groups of criteria.

Genes listed in conjunction with the neonatal lethality, impaired growth or failure to thrive and embryonic lethality are not considered further. This phenotypic information is not sufficiently specific at this point in time, because it is difficult to envision a mechanism connecting the genes in question to esophageal muscle development in the absence of further esophagus-specific information. Therefore, additional studies, involving a large number of participants (e.g., via the IMPC, International Mouse Phenotyping Consortium), are required to obtain more detailed information on the potential involvement of each of the identified genes in processes that are specific

## *Esophageal striated muscle*

to esophageal muscle development. In fact, in our recent publication we discussed future directions for an approach of study analogous to the current one (Baguma-Nibasheka et al., 2016).

Lastly, the involvement of neurotrophic factors, as previously reported (Reddy and Kablar, 2004), was not confirmed in the current study, in spite of the fact that NT-3 appeared to be involved in esophageal striated muscle development (Reddy and Kablar, 2004; Angka and Kablar, 2007, 2009 and data not shown).

---

*Acknowledgements.* We are grateful to the following individuals for their expert technical help at various stages of this work: Heather E. Angka (Dalhousie University, Halifax) and Dr. Roberta Nardacci (TEM Laboratory, Spallanzani Hospital, Rome). We thank Dr. Irena Rot and Dr. Bruce Greenfield for critical reading of the manuscript, and Mr. Giuseppe (Pino) Belluomo Anello for establishing contacts enabling aspects of this work. This work was funded by an operating grant from the National Science and Engineering Research Council of Canada (NSERC), and the infrastructure grants from the Canada Foundation for Innovation (CFI) and the Dalhousie Medical Research Foundation (DMRF) to BK. The authors also thank the Department of Medical Neuroscience (Dalhousie University, Halifax) for the support.

---

### References

- Acakpo-Satchivi L.J., Edelmann W., Sartorius C., Lu B.D., Wahr P.A., Watkins S.C., Metzger J.M., Leinwand L. and Kucherlapati R. (1997). Growth and muscle defects in mice lacking adult myosin heavy chain genes. *J. Cell Biol.* 139, 1219-1229.
- An M.C., Lin W., Yang J., Dominguez B., Padgett D., Sugiura Y., Aryal P., Gould T.W., Oppenheim R.W., Hester M.E., Kaspar B.K., Ko C.P. and Lee K.F. (2010). Acetylcholine negatively regulates development of the neuromuscular junction through distinct cellular mechanisms. *Proc. Natl. Acad. Sci. USA* 107, 10702-10707.
- Angka H.E. and Kablar B. (2007). Differential responses to the application of exogenous NT-3 are observed for subpopulations of motor and sensory neurons depending on the presence of skeletal muscle. *Dev. Dyn.* 236, 1193-1202.
- Angka H.E. and Kablar B. (2009). Role of skeletal muscle in the epigenetic shaping of motor neuron fate choices. *Histol. Histopathol.* 24, 1579-1592.
- Arber S., Hunter J.J., Ross J. Jr, Hongo M., Sansig G., Borg J., Perriard J.C., Chien K.R. and Caroni P. (1997). MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. *Cell* 88, 393-403.
- Azam M., Andrabi S.S., Sahr K.E., Kamath L., Kuliopulos A. and Chishti A.H. (2001). Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. *Mol. Cell Biol.* 21, 2213-2220.
- Babu G.J., Bhupathy P., Timofeyev V., Petrashevskaya N.N., Reiser P.J., Chiamvimonvat N. and Periasamy M. (2007). Ablation of sarcolipin enhances sarcoplasmic reticulum calcium transport and atrial contractility. *Proc. Natl. Acad. Sci. USA* 104, 17867-17872.
- Baguma-Nibasheka M., Fracassi A., Costain W.J., Moreno S. and Kablar B. (2016). Role of skeletal muscle in motor neuron development. *Histol. Histopathol.* 31, 699-719.
- Basmanav F.B.Ü., Cau L., Tafazzoli A., Mechin M.C., Wolf S., Romano M.T., Valentin F., Wiegmann H., Huchenq A., Kandil R., Garcia Bartels N., Kilic A., George S., Falser D.J., Bergner S., Ferguson D.J.P., Oprisoreanu A.M., Wehner M., Thiele H., Altmüller J., Nürnberg P., Swan D., Houniet D., Buchner A., Weibel L., Wagner N., Grimalt R., Bygum A., Serre G., Blume-Peytavi U., Sprecher E., Schoch S., Oji V., Hamm H., Farrant P., Simon M. and Betz R.C. (2016). Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome. *Am. J. Hum. Genet.* 99, 1292-1304.
- Blaschke R.J., Hahurij N.D., Kuijper S., Just S., Wisse L.J., Deissler K., Maxelon T., Anastasiadis K., Spitzer J., Hardt S.E., Scholer H., Feitsma H., Rottbauer W., Blum M., Meijlink F., Rappold G. and Gittenberger-de Groot A.C. (2007). Targeted mutation reveals essential functions of the homeodomain transcription factor Shox2 in sinoatrial and pacemaking development. *Circulation* 115, 1830-1838.
- Carroll E.A., Gerrelli D., Gasca S., Berg E., Beier D.R., Copp A.J. and Klingensmith J. (2003). Cordon-bleu is a conserved gene involved in neural tube formation. *Dev. Biol.* 262, 16-31.
- Carroll T.J., Park J.S., Hayashi S., Majumdar A. and McMahon A.P. (2005). Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. *Dev. Cell* 9, 283-292.
- Chihara D., Romer A.I., Bentzinger C.F., Rudnicki M.A. and Krauss R.S. (2015). PAX7 is required for patterning the esophageal musculature. *Skelet. Muscle* 5, 39
- Cho Y.Y., Kang M.J., Sone H., Suzuki T., Abe M., Igarashi M., Tokunaga T., Ogawa S., Takei Y.A., Miyazawa T., Sasano H., Fujino T. and Yamamoto T.T. (2001). Abnormal uterus with polycysts, accumulation of uterine prostaglandins, and reduced fertility in mice heterozygous for acyl-CoA synthetase 4 deficiency. *Biochem. Biophys. Res. Commun.* 284, 993-997.
- Chuang C.H., Wallace M.D., Abratte C., Southard T. and Schimenti J.C. (2010). Incremental genetic perturbations to MCM2-7 expression and subcellular distribution reveal exquisite sensitivity of mice to DNA replication stress. *PLoS Genet.* 6, 9.
- Clotman F., Jacquemin P., Plumb-Rudewicz N., Pierreux C.E., Van der Smissen P., Dietz H.C., Courtoy P.J., Rousseau G.G. and Lemaigre F.P. (2005). Control of liver cell fate decision by a gradient of TGFbeta signaling modulated by Onecut transcription factors. *Genes Dev.* 19, 1849-1854.
- Crawford K., Flick R., Close L., Shelly D., Paul R., Bove K., Kumar A. and Lessard J. (2002). Mice lacking skeletal muscle actin show reduced muscle strength and growth deficits and die during the neonatal period. *Mol. Cell Biol.* 22, 5887-5896.
- Donald S., Humby T., Fyfe I., Segonds-Pichon A., Walker S.A., Andrews S.R., Coadwell W.J., Emson P., Wilkinson L.S. and Welch H.C. (2008). P-Rex2 regulates Purkinje cell dendrite morphology and motor coordination. *Proc. Natl. Acad. Sci. USA* 105, 4483-4488.
- Dusing M.R., Maier E.A., Aronow B.J. and Wiginton D.A. (2010). Onecut-2 knockout mice fail to thrive during early postnatal period and have altered patterns of gene expression in small intestine. *Physiol. Genomics* 42, 115-1125.
- Edgar R., Domrachev M. and Lash A.E. (2002). Gene expression omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 30, 207-210.
- Fox M.A., Sanes J.R., Borza D.B., Eswarakumar V.P., Fassler R., Hudson B.G., John S.W., Ninomiya Y., Pedchenko V., Pfaff S.L., Rheault M.N., Sado Y., Segal Y., Werle M.J. and Umemori H. (2007). Distinct target-derived signals organize formation,

*Esophageal striated muscle*

- maturation, and maintenance of motor nerve terminals. *Cell* 129, 179-193.
- Frey N., Barrientos T., Shelton J.M., Frank D., Rutten H., Gehring D., Kuhn C., Lutz M., Rothermel B., Bassel-Duby R., Richardson J.A., Katus H.A., Hill J.A. and Olson E.N. (2004). Mice lacking calstabin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. *Nat. Med.* 10, 1336-1343.
- Fujihara Y., Murakami M., Inoue N., Satouh Y., Kaseda K., Ikawa M. and Okabe M. (2010). Sperm equatorial segment protein 1, SPESP1, is required for fully fertile sperm in mouse. *J. Cell Sci.* 123, 1531-1536.
- Gottlieb P.D., Pierce S.A., Sims R.J., Yamagishi H., Weihe E.K., Harriss J.V., Maika S.D., Kuziel W.A., King H.L., Olson E.N., Nakagawa O. and Srivastava D. (2002). Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. *Nat. Genet.* 31, 25-32.
- Hack A.A., Ly C.T., Jiang F., Clendenin C.J., Sigrist K.S., Wollmann R.L. and McNally E.M. (1998). Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. *J. Cell Biol.* 142, 1279-1287.
- Hasty P., Bradley A., Morris J.H., Edmondson D.G., Venuti J.M., Olson E.N. and Klein W.H. (1993). Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature* 364, 501-506.
- Hook J., Lemckert F., Qin H., Schevzov G. and Gunning P. (2004). Gamma tropomyosin gene products are required for embryonic development. *Mol. Cell Biol.* 24, 2318-2323.
- Hu X., Eszterhas S., Pallazzi N., Bouhassira E.E., Fields J., Tanabe O., Gerber S.A., Bulger M., Engel J.D., Groudine M. and Fiering S. (2007). Transcriptional interference among the murine beta-like globin genes. *Blood* 109, 2210-2216.
- Huynh N.N., Andrews K.L., Head G.A., Khong S.M., Mayorov D.N., Murphy A.J., Lambert G., Kiriazis H., Xu Q., Du X.J. and Chin-Dusting J.P. (2009). Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. *Hypertension* 54, 294-301.
- Inanlou M.R. and Kablar B. (2005). Abnormal development of the intercostal muscles and the rib cage in *Myf5*<sup>-/-</sup> embryos leads to pulmonary hypoplasia. *Dev. Dyn.* 232, 43-54.
- Jiang P., Song J., Gu G., Slonimsky E., Li E. and Rosenthal N. (2002). Targeted deletion of the MLC1f/3f downstream enhancer results in precocious MLC expression and mesoderm ablation. *Dev. Biol.* 243, 281-293.
- Jones W.K., Grupp I.L., Doetschman T., Grupp G., Osinska H., Hewett T.E., Boivin G., Gulick J., Ng W.A. and Robbins J. (1996). Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. *J. Clin. Invest.* 98, 1906-1917.
- Kablar B., Tajbakhsh S. and Rudnicki M.A. (2000). Transdifferentiation of esophageal smooth to skeletal muscle is myogenic bHLH factor-dependent. *Development* 127, 1627-1639.
- Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrlich M., Dobrovic A., Slavin J., Choong P.F., Simmons P.J., Dawid I.B. and Thomas D.M. (2009). Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. *J. Clin. Invest.* 119, 837-851.
- Kassar-Duchossoy L., Gayraud-Morel B., Gomes D., Rocancourt D., Buckingham M., Shinin V. and Tajbakhsh S. (2004). *Mrf4* determines skeletal muscle identity in *Myf5:MyoD* double-mutant mice. *Nature* 431, 466-471.
- Krauss R.S., Chihara D. and Romer A.I. (2016). Embracing change: striated-for-smooth muscle replacement in esophagus development. *Skelet. Muscle* 6, 27.
- Lane P.W. (1985). Muscular dystrophy with myositis (*mdm*). *Mouse News Lett.* 73, 18.
- Lin H.F., Maeda N., Smithies O., Straight D.L. and Stafford D.W. (1997). A coagulation factor IX-deficient mouse model for human hemophilia B. *Blood* 90, 3962-3966.
- Malaval L., Wade-Gu ye N.M., Boudiffa M., Fei J., Zirngibl R., Chen F., Laroche N., Roux J.P., Burt-Pichat B., Duboeuf F., Boivin G., Jurdic P., Lafage-Proust M.H., Amedee J., Vico L., Rossant J. and Aubin J.E. (2008). Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. *J. Exp. Med.* 205, 1145-1153.
- Mansouri A., Stoykova A., Torres M. and Gruss P. (1996). Dysgenesis of cephalic neural crest derivatives in *Pax7*<sup>-/-</sup> mutant mice. *Development* 122, 831-838.
- Moza M., Mologni L., Trokovic R., Faulkner G., Partanen J. and Carpen O. (2007). Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice. *Mol. Cell Biol.* 27, 244-252.
- Niederkofer V., Salie R. and Arber S. (2005). Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. *J. Clin. Invest.* 115, 2180-2186.
- Oddoux S., Brocard J., Schweitzer A., Szentesi P., Giannesini B., Brocard J., Faure J., Pernet-Gallay K., Bendahan D., Lunardi J., Csernoch L. and Marty I. (2009). Triadin deletion induces impaired skeletal muscle function. *J. Biol. Chem.* 284, 34918-34929.
- Pajeroski A.G., Nguyen C., Aghajanian H., Shapiro M.J. and Shapiro V.S. (2009). NKAP is a transcriptional repressor of notch signaling and is required for T cell development. *Immunity* 30, 696-707.
- Palmer S., Groves N., Schindeler A., Yeoh T., Biben C., Wang C.C., Sparrow D.B., Barnett L., Jenkins N.A., Copeland N.G., Koentgen F., Mohun T. and Harvey R.P. (2001). The small muscle-specific protein Csl modifies cell shape and promotes myocyte fusion in an insulin-like growth factor 1-dependent manner. *J. Cell Biol.* 153, 985-998.
- Pan Y., Zvaritch E., Tupling A.R., Rice W.J., de Leon S., Rudnicki M., McKerlie C., Banwell B.L. and MacLennan D.H. (2003). Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca<sup>2+</sup> ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice. *J. Biol. Chem.* 278, 13367-13375.
- Pappas C.T., Mayfield R.M., Henderson C., Jamilpour N., Cover C., Hernandez Z., Hutchinson K.R., Chu M., Nam K.H., Valdez J.M., Wong P.K., Granzier H.L. and Gregorio C.C. (2015). Knockout of *Lmod2* results in shorter thin filaments followed by dilated cardiomyopathy and juvenile lethality. *Proc. Natl. Acad. Sci. USA* 112, 13573-13578.
- Patapoutian A., Wold B.J. and Wagner R.A. (1995). Evidence for developmentally programmed transdifferentiation in mouse esophageal muscle. *Science* 270, 1818-1821.
- Pfaff S.L., Mendelsohn M., Stewart C.L., Edlund T. and Jessell T.M. (1996). Requirement for LIM homeobox gene *Isl1* in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation. *Cell* 84, 309-320.
- Pondarre C., Antiochos B.B., Campagna D.R., Clarke S.L., Greer E.L.,

## *Esophageal striated muscle*

- Deck K.M., McDonald A., Han A.P., Medlock A., Kutok J.L., Anderson S.A., Eisenstein R.S. and Fleming M.D. (2006). The mitochondrial ATP-binding cassette transporter *Abcb7* is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. *Hum. Mol. Genet.* 15, 953-964.
- Pruitt S.C., Bailey K.J. and Freeland A. (2007). Reduced *Mcm2* expression results in severe stem/progenitor cell deficiency and cancer. *Stem Cells* 25, 3121-3132.
- Quinn M.E., Goh Q., Kurosaka M., Gamage D.G., Petrany M.J., Prasad V. and Millay D.P. (2017). Myomerger induces fusion of non-fusogenic cells and is required for skeletal muscle development. *Nat. Commun.* 8, 15665.
- Radford N.B., Wan B., Richman A., Szczepaniak L.S., Li J.L., Li K., Pfeiffer K., Schagger H., Garry D.J. and Moreadith R.W. (2002). Cardiac dysfunction in mice lacking cytochrome-c oxidase subunit *VlaH*. *Am. J. Physiol. Heart Circ. Physiol.* 282, H726-733.
- Rainey M.A., George M., Ying G., Akakura R., Burgess D.J., Siefker E., Bargar T., Doglio L., Crawford S.E., Todd G.L., Govindarajan V., Hess R.A., Band V., Naramura M. and Band H. (2010). The endocytic recycling regulator *EHD1* is essential for spermatogenesis and male fertility in mice. *BMC Dev. Biol.* 10, 37.
- Ramirez-Martinez A., Cenik B.K., Bezprozvannaya S., Chen B., Bassel-Duby R., Liu N. and Olson E.N. (2017). *KLHL41* stabilizes skeletal muscle sarcomeres by nonproteolytic ubiquitination. *eLife* 6, e26439.
- Reddy T. and Kablar B. (2004). Evidence for the involvement of neurotrophins in muscle transdifferentiation and acetylcholine receptor transformation in the esophagus of *Myf5<sup>-/-</sup>:MyoD<sup>-/-</sup>* and *NT-3<sup>-/-</sup>* embryos. *Dev. Dyn.* 231, 683-692.
- Rudnicki M.A., Schnegelsberg P.N., Stead R.H., Braun T., Arnold H.H. and Jaenisch R. (1993). *MyoD* or *Myf-5* is required for the formation of skeletal muscle. *Cell* 75, 1351-1359.
- Seale P., Ishibashi J., Holterman C. and Rudnicki M.A. (2004). Muscle satellite cell-specific genes identified by genetic profiling of *MyoD*-deficient myogenic cell. *Dev. Biol.* 275, 287-300.
- Shi O., Morris S.M. Jr, Zoghbi H., Porter C.W. and O'Brien W.E. (2001). Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. *Mol. Cell Biol.* 21, 811-813.
- Su A.I., Cooke M.P., Ching K.A., Hakak Y., Walker J.R., Wiltshire T., Orth A.P., Vega R.G., Sapinoso L.M., Moqrich A., Patapoutian A., Hampton G.M., Schultz P.G. and Hogenesch J.B. (2002). Large-scale analysis of the human and mouse transcriptomes. *Proc. Natl. Acad. Sci. USA* 99, 4465-4470.
- Swiatek P.J. and Gridley T. (1993). Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene *Krox20*. *Genes Dev.* 7, 2071-2084.
- Takekura H., Iino M., Takekura H., Nishi M., Kuno J., Minowa O., Takano H. and Noda T. (1994). Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. *Nature* 369, 556-559.
- Tseng B.S., Cavin S.T., Booth F.W., Olson E.N., Marin M.C., McDonnell T.J. and Butler I.J. (2000). Pulmonary hypoplasia in the myogenin null mouse embryo. *Am. J. Respir. Cell Mol. Biol.* 22, 304-315.
- Toth M., Grimsby J., Buzsaki G. and Donovan G.P. (1995). Epileptic seizures caused by inactivation of a novel gene, *jerky*, related to centromere binding protein-B in transgenic mice. *Nat. Genet.* 11, 71-75.
- Wang Y., Szczesna-Cordary D., Craig R., Diaz-Perez Z., Guzman G., Miller T. and Potter J.D. (2007). Fast skeletal muscle regulatory light chain is required for fast and slow skeletal muscle development. *FASEB J.* 21, 2205-2214.
- Weinert S., Bergmann N., Luo X., Erdmann B. and Gotthardt M. (2006). M line-deficient titin causes cardiac lethality through impaired maturation of the sarcomere. *J. Cell Biol.* 173, 559-570.
- Wigle J.T. and Oliver G. (1999). *Prox1* function is required for the development of the murine lymphatic system. *Cell* 98, 769-778.
- Witt C.C., Burkart C., Labeit D., McNabb M., Wu Y., Granzier H. and Labeit S. (2006). Nebulin regulates thin filament length, contractility, and Z-disk structure in vivo. *EMBO J.* 25, 3843-3855.
- Witt C.C., Witt S.H., Lerche S., Labeit D., Back W. and Labeit S. (2008). Cooperative control of striated muscle mass and metabolism by *MuRF1* and *MuRF2*. *EMBO J.* 27, 350-360.
- Wörl J. and Neuhuber W.L. (2005). Ultrastructural analysis of the smooth-to-striated transition zone in the developing mouse esophagus: emphasis on apoptosis of smooth and origin and differentiation of striated muscle cells. *Dev. Dyn.* 233, 964-982.
- Wörl J., Breuer C. and Neuhuber W.L. (2009). Deletion of *Pax7* changes the tunica muscularis of the mouse esophagus from an entirely striated into a mixed phenotype. *Dev. Dyn.* 238, 864-874.
- [www.informatics.jax.org\(a\): www.informatics.jax.org/javawi2/servlet/WIFetch?page=alleleDetail&key=813000](http://www.informatics.jax.org(a): www.informatics.jax.org/javawi2/servlet/WIFetch?page=alleleDetail&key=813000)
- Yoshida M., Minamisawa S., Shimura M., Komazaki S., Kume H., Zhang M., Matsumura K., Nishi M., Saito M., Saeki Y., Ishikawa Y., Yanagisawa T. and Takeshima H. (2005). Impaired  $Ca^{2+}$  store functions in skeletal and cardiac muscle cells from sarcalumenin-deficient mice. *J. Biol. Chem.* 280, 3500-3506.
- Zhang B., Zheng C., Zhu M., Tao J., Vasievich M.P., Baines A., Kim J., Schekman R., Kaufman R.J. and Ginsburg D. (2011). Mice deficient in *LMAN1* exhibit FV and FVIII deficiencies and liver accumulation of  $\alpha_1$ -antitrypsin. *Blood* 118, 3384-3391.
- Zhou Q., Chu P.H., Huang C., Cheng C.F., Martone M.E., Knoll G., Shelton G.D., Evans S. and Chen J. (2001). Ablation of *Cypher*, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. *J. Cell Biol.* 155, 605-612.
- Zhu Q., Couillard-Despres S. and Julien J.P. (1997). Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. *Exp. Neurol.* 148, 299-316.